UNITED STATES SECURITIES AND EXCHANGE
COMMISSION Washington, D.C. 20549  FORM 10-Q  (Mark One) SQUARTERLY REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2008  OR  £TRANSITION REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to
___________  Commission File Number333-150483  Noble Medical Technologies
,
Inc. (Name of small business issuer in its
charter)  Delaware

20-0587718(State or Other Jurisdiction of

(I.R.S. Employer Identification
No.)Incorporation or Organization)  4430 Noble Avenue  Apartment 201 Sherman Oaks, CA 91403 (Address of Principal Executive Offices)  310-498-0778 (Issuer's Telephone Number, Including Area
Code)  Check whether the issuer (1) filed all
reports required to be filed by Section 13 or 15(d) of the Exchange Act during
the past 12 months (or for such shorter period that the registrant was required
to file such reports), and (2) has been subject to such filing requirements for
the past 90 days. YES S NO o  Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer or a smaller
reporting company filer.  See definition of accelerated filer and
large accelerated filer in Rule 12b-2 of the Exchange Act (Check one):  Large Accelerated Filer £    Accelerated Filer
£
       Non-Accelerated Filer £
        Smaller Reporting Company S  Indicate by check mark whether the registrant is a shell
company (as defined in Rule 12b-2 of the Exchange Act). YES S  NO £  State the number of shares outstanding of each of the
issuers classes of common equity, as of the latest practicable date: 4,188,000
shares of common stock, par value $.0001 per share, as of June 16, 2008.  Transitional Small Business Disclosure
Format (Check one). YES o NO S  1    Noble Medical Technologies,
Inc.FORM 10-QMarch 31, 2008INDEXPART I-- FINANCIAL INFORMATIONItem 1.

Financial Statements

4Item 2.

Managements Discussion and Analysis of Financial
Condition

12Item 3

Quantitative and Qualitative Disclosures About
Market Risk

14Item 4.

Control and Procedures

14PART II-- OTHER INFORMATIONItem 1

Legal Proceedings

15Item 2.

Unregistered Sales of Equity Securities and Use of
Proceeds

15Item 3.

Defaults Upon Senior Securities

15Item 4.

Submission of Matters to a Vote of Security
Holders

15Item 5.

Other Information

15Item 6.

Exhibits and Reports on Form 8-K

16SIGNATURE



16   2   NOBLE MEDICAL
TECHNOLOGIES, INC.  (A DEVELOPMENT STAGE COMPANY)    March 31, 2008   INDEX TO FINANCIAL STATEMENTS  Contents
Page(s)Balance Sheets at March 31, 2008 ( Unaudited) and
December 31, 2007
4Statements of Operations for the Three Months Ended
March 31, 2008 (Unaudited) and for the Period from July 25, 2007
(Inception) through March 31, 2008 (Unaudited)
5Statement of Stockholders Deficit for the Period
from July 25, 2007 (Inception) through March 31, 2008 (Unaudited)
6Statement of Cash Flows for the Three Months Ended
March 31, 2008 (Unaudited) and for the Period from July 25, 2007
(Inception) through March 31, 2008 (Unaudited)
7Notes to the Financial Statements
(Unaudited)
8     3    NOBLE MEDICAL TECHNOLOGIES,
INC.(A DEVELOPMENT STAGE
COMPANY)BALANCE SHEETSMarch 31,
2008

December 31,
2007(Unaudited)ASSETSCURRENT ASSETS:Cash

$
12,503
$
2,093Total Current Assets

12,503

2,093Total Assets
$
12,503
$
2,093LIABILITIES AND STOCKHOLDERS' DEFICITCURRENT LIABILITIES:Accrued expenses
$
7,000
$
28,200Total Current Liabilities

7,000

28,200STOCKHOLDERS' EQUITY (DEFICIT):Preferred stock at $0.0001 par value: 1,000,000
sharesauthorized, none issued or outstanding

-

-Common stock at $0.0001 par value: 20,000,000
shares,authorized 4,172,000 and 4,008,000 shares issued
and outstanding, respectively

417

401Additional paid-in capital

42,583

1,599Deficit accumulated during the development
stage

(37,497)

(28,107)Total Stockholders' Equity (Deficit)

5,503

(26,107)Total Liabilities and Stockholders' Equity
(Deficit)
$
12,503
$
2,093  See accompanying notes to the financial
statements  4      NOBLE MEDICAL TECHNOLOGIES, INC.(A DEVELOPMENT STAGE COMPANY)STATEMENT OF OPERATIONS(UNAUDITED)For thePeriod fromJuly 25, 2007For the Three

(Inception)Months Ended

throughMarch 31, 2008

March 31, 2008OPERATING EXPENSES:Professional fees
$
2,000
$
30,100General and administrative expenses

7,390

7,397Total operating expenses

9,390

37,497LOSS FROM OPERATIONS

(9,390)

(37,497)INCOME TAXES

-

-NET LOSS
$
(9,390)
$
(37,497)NET LOSS PER COMMON SHARE -BASIC AND DILUTED:
$
(0.02)
$
(0.01)Weighted Common Shares Outstanding -basic and diluted

4,065,495

4,026,576  See accompanying notes to the financial
statements  5    NOBLE MEDICAL TECHNOLOGIES,
INC.(A DEVELOPMENT STAGE COMPANY)CONSOLIDATED STATEMENT OF
STOCKHOLDERS' DEFICITFor the Period from July 25, 2007
(Inception) through March 31, 2008(UNAUDITED)DeficitCommon Stock, $0.001



accumulated

TotalPar Value

Additional

During the

Stockholders'Number of



Paid-in

Development

EquityShares

Amount

Capital

Stage

(Deficit)Balance, July 25, 2007
-
$
-
$
-
$
-
$
-Issuance of common stock to  founders
4,000,000

400

(400)



-Issuance of common stock for cash
8,000

1

1,999



2,000July through December 2007
at $0.25 per shareNet loss






(28,107)

(28,107)Balance, December 31, 2007
4,008,000
$
401
$
1,599
$
(28,107)
$
(26,107)Issuance of common stock for cash
164,000

16

40,984



41,000January through March 2008
at $0.25 per shareNet loss






(9,390)

(9,390)Balance, March 31, 2008
4,172,000
$
417
$
42,583
$
(37,497)
$
5,503  See accompanying notes to the financial
statements  6    NOBLE MEDICAL TECHNOLOGIES, INC.(A DEVELOPMENT STAGE COMPANY)STATEMENT OF CASH FLOWS(UNAUDITED)For the Period from

For the Period fromJuly 25, 2007

July 25, 2007(Inception) through

(Inception) throughMarch 31,  2008

March 31, 2008CASH FLOWS FROM OPERATING ACTIVITIES:Net loss
$
(9,390)
$
(37,497)Adjustments to reconcile net loss to net cash
provided by(used in) operating activitiesChanges in operating assets and liabilities:Accrued expenses

(21,200)

7,000NET CASH PROVIDED BY (USED IN) OPERATING
ACTIVITIES

(30,590)

(30,497)CASH FLOWS FROM INVESTING ACTIVITIES:Purchases of property, plant and equipmentProceeds from disposal of property and
equipmentPatents rightsPurchase of land use rightPurchases of softwareNET CASH USED IN INVESTING ACTIVITIES

-

-CASH FLOWS FROM FINANCING ACTIVITIES:Amounts received from (paid to) related
partiesSale of common stock

41,000

43,000Contribution to capital

-

-NET CASH PROVIDED BY FINANCING ACTIVITIES

41,000

43,000NET CHANGE IN CASH

10,410

12,503Cash at beginning of period

2,093

-Cash at end of period
$
12,503
$
12,503SUPPLEMENTAL DISCLOSURE OF
CASH FLOW
INFORMATION:Interest paid
$
-
$
-Taxes paid
$
-
$
-  See accompanying notes to the financial
statements  7     NOBLE MEDICAL TECHNOLOGIES, INC. (A DEVELOPMENT STAGE COMPANY) Notes to the Financial Statements March 31, 2008 (Unaudited)     NOTE 1 - ORGANIZATION AND
OPERATIONS   Noble Medical
Technologies, Inc. (a development stage company) (Noble Medical or the
Company) was incorporated on July 25, 2007 under the laws of the State of
Delaware.  A substantial portion of the Companys activities has involved
developing a business plan and establishing contacts and visibility in the
marketplace and the Company has not generated any revenue to date. The Company
plans to engage in developing and marketing enhancements to electrocardiogram
(EKG) equipment that will be directed towards medical technicians at hospitals
and other locations where EKG equipment is used.   NOTE 2 - SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES    Basis of presentation  The accompanying
unaudited financial statements and related notes have been prepared in
accordance with accounting principles generally accepted in the United States of
America (U.S. GAAP) for interim financial information, and with the rules and
regulations of the United States Securities and Exchange Commission (SEC) to
Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all
of the information and footnotes required by U.S. GAAP for complete financial
statements.  In the opinion of management, all adjustments (consisting of
normal recurring accruals) considered necessary for a fair presentation of the
financial position, results of operations and cash flows for the interim periods
have been included.  These financial statements should be read in
conjunction with the financial statements of the Company for the year ended
December 31, 2007 and notes thereto contained in the Companys Registration
Statement on Form S-1 as filed with the SEC on April 28, 2008, which was
declared effective on May 6, 2008.  Interim results are not necessarily
indicative of the results for the full year.  Reclassification  Certain amounts in the
prior period financial statements have been reclassified to conform to the
current period presentation. These reclassifications had no effect on reported
losses.  Development stage company  The Company is a
development stage company as defined by Statement of Financial Accounting
Standards No. 7Accounting and Reporting by Development Stage Enterprises(SFAS No. 7).  The Company is still devoting substantially all of its
efforts on establishing the business and its planned principal operations have
not commenced.  All losses accumulated since inception have been considered
as part of the Company's development stage activities.  Use of estimates  The preparation of
financial statements in conformity with generally accepted accounting principles
requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and
liabilities at the date of the financial statements and the reported amounts of
revenues and expenses during the reporting period.  Actual results could
differ from those estimates.  Due to the limited level
of operations, the Company has not had to make material assumptions or estimates
other than the assumption that the Company is a going concern.     Cash equivalents   The Company considers
all highly liquid investments with a maturity of three months or less when
purchased to be cash equivalents.  8   Fair value
of financial instruments  The fair value of a
financial instrument is the amount at which the instrument could be exchanged in
a current transaction between willing parties.  The carrying amounts of
financial assets and liabilities, such as cash and accrued expenses, approximate
their fair values because of the short maturity of these instruments and market
rates of interest.     Revenue recognition   The Company follows the
guidance of the Securities and Exchange Commissions Staff Accounting Bulletin
(SAB) No. 101 Revenue Recognition (SAB No. 101), as amended by SAB
No. 104 (SAB No. 104) for revenue recognition.  The Company will record
revenue when persuasive evidence of an arrangement exists, product delivery has
occurred and the title and risk of loss transfer to the buyer, the sales price
to the customer is fixed or determinable, and collectability is reasonably
assured.  The Company will derive
its revenue from sales contracts with customers with revenues being generated
upon the shipment of goods. Persuasive evidence of an arrangement is
demonstrated via invoice, product delivery is evidenced by warehouse shipping
log as well as a signed bill of lading from the trucking company or third party
carrier and title transfers upon shipment, based on free on board (FOB)
factory; the sales price to the customer is fixed upon acceptance of the
purchase order and there is no separate sales rebate, discount, or volume
incentive.   Net loss per common share  Net loss per common
share is computed pursuant to Statement of Financial Accounting Standards No.
128 Earnings Per Share (SFAS No. 128).  Basic net loss per share
is computed by dividing net loss by the weighted average number of shares of
common stock outstanding during the period. Diluted net loss per share is
computed by dividing net loss by the weighted average number of shares of common
stock and potentially outstanding shares of common stock during each period.
There were no potentially dilutive shares outstanding as of March 31, 2008.  Recently issued accounting
pronouncements          In June 2003, the
Securities and Exchange Commission (SEC) adopted final rules under Section 404
of the Sarbanes-Oxley Act of 2002 (Section 404), as amended by SEC Release No.
33-8889 on February 1, 2008.  Commencing with its annual report for the
year ending December 31, 2008, the Company will be required to include a report
of management on its internal control over financial reporting. The internal
control report must include a statement  · of managements
responsibility for establishing and maintaining adequate internal control over
its financial reporting;  · of managements
assessment of the effectiveness of its internal control over financial reporting
as of year end; and  · of the framework used
by management to evaluate the effectiveness of the Companys internal control
over financial reporting.  Furthermore, in the
following fiscal year, it is required to file the auditors attestation report
separately on the Companys internal control over financial reporting on whether
it believes that the Company has maintained, in all material respects, effective
internal control over financial reporting.   On September 15, 2006,
the Financial Accounting Standards Board (FASB) issued FASB Statement No. 157
Fair Value Measurements (SFAS No. 157).  SFAS No. 157
defines fair value, establishes a framework for measuring fair value and expands
disclosures about fair value measurements.  SFAS No. 157 is effective
as of the beginning of the first fiscal year beginning after November 15,
2007.  The Company does not anticipate that the adoption of this
statement will have a material effect on the Companys financial condition and
results of operations.  9   On February 15, 2007, the FASB issued FASB Statement No. 159The Fair Value Option for Financial Assets and Financial Liabilities: Including
an amendment of FASB Statement No. 115 (SFAS No. 159). SFAS No. 159
permits all entities to elect to measure many financial instruments and certain
other items at fair value with changes in fair value reported in earnings. SFAS
No. 159 is effective as of the beginning of the first fiscal year that begins
after November 15, 2007, with earlier adoption permitted. The Company does not
anticipate that the adoption of this statement will have a material effect on
the Companys financial condition and results of operations.  In June 2007, the
Emerging Issues Task Force of the FASB issued EITF Issue No. 07-3 Accounting
for Nonrefundable Advance Payments for Goods or Services to be Used in Future
Research and Development Activities (EITF Issue No. 07-3) which is
effective for fiscal years beginning after December 15, 2007.  EITF
Issue No. 07-3 requires that nonrefundable advance payments for future research
and development activities be deferred and capitalized.  Such amounts
will be recognized as an expense as the goods are delivered or the related
services are performed.  The Company does not expect the adoption of
EITF Issue No. 07-3 to have a material impact on the financial results of the
Company.  In December 2007, the
FASB issued FASB Statement No. 141 (Revised 2007)Business Combinations
(SFAS No. 141(R)), which requires the Company to record fair value estimates
of contingent consideration and certain other potential liabilities during the
original purchase price allocation, expense acquisition costs as incurred and
does not permit certain restructuring activities previously allowed under
Emerging Issues Task Force Issue No. 95-3 to be recorded as a component of
purchase accounting.  SFAS No. 141(R) applies prospectively to
business combinations for which the acquisition date is on or after the
beginning of the first annual reporting period beginning on or after December
15, 2008, except for the presentation and disclosure requirements, which shall
be applied retrospectively for all periods presented. The Company will adopt
this standard at the beginning of the Companys year ending December 31, 2008
for all prospective business acquisitions. The Company has not determined the
effect that the adoption of SFAS No. 141(R) will have on the financial results
of the Company.  In December 2007, the
FASB issued FASB Statement No. 160Noncontrolling Interests in Consolidated
Financial Statements - an amendment of ARB No. 51 (SFAS No. 160), which
causes noncontrolling interests in subsidiaries to be included in the equity
section of the balance sheet.  SFAS No. 160 applies prospectively to
business combinations for which the acquisition date is on or after the
beginning of the first annual reporting period beginning on or after December
15, 2008, except for the presentation and disclosure requirements, which shall
be applied retrospectively for all periods presented.  The Company will
adopt this standard at the beginning of the Companys year ending December 31,
2008 for all prospective business acquisitions.  The Company has not
determined the effect that the adoption of SFAS No. 160 will have on the
financial results of the Company.   Management does not
believe that any recently issued, but not yet effective accounting
pronouncements, if adopted, would have a material effect on the accompanying
financial statements.  NOTE 3  DEVELOPMENT STAGE ACTIVITIES
AND GOING CONCERN  The Company is currently
in the development stage. The Company intends to market enhancements to
electrocardiogram (EKG) equipment that will be directed towards medical
technicians at hospitals and other locations where EKG equipment is used;
however, the Company has not yet acquired the customers or begun operations.
 Its activities as of March 31, 2008 have been organizational and
developmental (pre-operational).  As reflected in the
accompanying financial statements, the Company had a deficit accumulated during
the development stage of $37,497 at March 1, 2008 and had a net loss of $9,390
for the three months ended March 31, 2008.  While the Company is
attempting to commence operations and produce revenues, the Companys cash
position may not be significant enough to support the Companys daily
operations. Management intends to raise additional funds by way of a public or
private offering.  Management believes that the actions presently being
taken to further implement its business plan and generate revenues provide the
opportunity for the Company to continue as a going concern. While the Company
believes in the viability of its strategy to increase revenues and in its
ability to raise additional funds, there can be no assurances to that effect.
The ability of the Company to continue as a going concern is dependent upon the
Companys ability to further implement its business plan and generate revenues.
The financial statements do not include any adjustments that might be necessary
if the Company is unable to continue as a going concern.  10   NOTE 4 
STOCKHOLDERS EQUITY (DEFICIT)  Common stock  The Company was
incorporated on July 25, 2007 at which time 4,000,000 shares of common stock
were issued to the Companys founders.  No value was given to the shares
issued by the newly formed corporation.  Therefore, the shares were
recorded to reflect the $.0001 par value and paid in capital was recorded as a
negative amount ($400).  In other words, no net value was assigned to these
shares.  For the period from July
25, 2007 through December 31, 2007, the Company sold 8,000 shares of its common
stock in a private placement at $0.25 per share to two (2) individuals for
$2,000.  For the period from
January 1, 2008 through March 31, 2008, the Company sold 164,000 shares of its
common stock at $0.25 per share to 36 individuals for $41,000.       NOTE 5  RELATED PARTY
TRANSACTION  Office space  The Company has been
provided office space by its Chief Executive Officer at no cost.  NOTE 6  SUBSEQUENT EVENT  For the period from
April 1, 2008 through April 17, 2008, the Company sold 16,000 shares of its
common stock at $0.25 per share to 4 individuals for $4,000.   11   Item 2 
Managements Discussion and Analysis or Plan of Operation of Financial Condition
and Results of Operations  References to Company, we or us refer
to Noble Medical Products, Inc., unless the context requires otherwise.  MANAGEMENTS DISCUSSION AND ANALYSIS OR
PLAN OF OPERATION AND RESULTS OF OPERATIONS  MANAGEMENTS DISCUSSION AND ANALYSIS OR
PLAN OF OPERATION  Managements Discussion and Analysis
contains statements that are forward-looking. These statements are based on
current expectations and assumptions that are subject to risks and
uncertainties. Actual results could differ materially because of factors
discussed in Factors That May Affect Future Results and Financial
Condition.  OVERVIEW  We are in a developmental stage.
Implementing our planned business operation is dependant on the effectiveness of
this registration statement and our ability to raise between $600,000 and
$2,000,000 of additional capital after all offering expenses paid to a placement
agent, attorneys, accountants and the like.  Our plan is to utilize such capital we
raise as follows:  If a Net of

If a Net of$600,000 is Raised

$2,000,000 is RaisedRenting and Furnishing Offices
$
150,000
$
250,000Patent Application
$
20,000
$
20,000FDA Compliance
$
15,000
$
15,000Equipment
$
80,000
$
28
0,000Officer Salaries
$
100,000
$
250,000Marketing Expense
$
135,000
$
725,000Working Capital
$
100,000
$
4 5

0,000  The foregoing are estimates only and any
funds may be reallocated based upon managements evaluation of then existing
conditions.  To date our capital raising efforts have
not been successful and we have not commenced our business operations.  INFLATION  Inflation can be expected to have an impact
on our operating costs. A prolonged period of inflation could cause a general
economic downturn and negatively impact our results. However, the effect of
inflation has been minimal over the past three years.  SEASONALITY  We do not believe that our business will be
seasonal to any material degree.  12   Going
Concern  Our financial statements have been prepared
on a going concern basis, which contemplates the realization of assets and the
satisfaction of liabilities in the normal course of business. We have a history
of losses that are likely to continue in the future. Our independent registered
public accounting firm has included a footnote in their report in our audited
financial statements for the year ended December 31, 2007 to the effect that our
losses from operations and our negative cash flows from operations raise
substantial doubt about our ability to continue as a going concern. Our
financial statements do not include any adjustments that might be necessary
should we be unable to continue as a going concern. If we were to unable to
continue as a going concern, our shareholders would be likely to realize less
for our assets than they are currently carried on our books because they would
be sold separate from any operating business. We may be required to cease
operations which could result in our shareholders losing almost all of their
investment.  Comparison of Periods, Year to Year  We were not in existence during the
corresponding period in the prior year and therefore cannot make a year-to-year
comparison of our results.  Liquidity and Capital Resources  As of March 31, 2008, we had $12,503 cash
on hand and $7,000 in accrued expenses.  Off Balance Sheet Arrangements  None  Forward-Looking Statements  FORWARD LOOKING STATEMENT INFORMATION  Certain statements made in this Report on
Form 10-Q are forward-looking statements (within the meaning of the Private
Securities Litigation Reform Act of 1995) regarding the plans and objectives of
management for future operations. Such statements involve known and unknown
risks, uncertainties and other factors that may cause our actual results,
performance or achievements to be materially different from any future results,
performance or achievements expressed or implied by such forward-looking
statements. The forward-looking statements included herein are based on current
expectations that involve numerous risks and uncertainties. Our plans and
objectives are based, in part, on assumptions involving judgments with respect
to, among other things, future economic, competitive and market conditions,
technological developments related to cellular telephone or other mobile
communications, and future business decisions, all of which are difficult or
impossible to predict accurately and many of which are beyond our control.  Although we believe that our assumptions
underlying the forward-looking statements are reasonable, any of the assumptions
could prove inaccurate and, therefore, there can be no assurance that the
forward-looking statements included in this prospectus will prove to be
accurate. In light of the significant uncertainties inherent in the
forward-looking statements included herein particularly in view of the current
state of our operations, the inclusion of such information should not be
regarded as a statement by us or any other person that our objectives and plans
will be achieved. Factors that could cause actual results to differ materially
from those expressed or implied by such forward-looking statements include, but
are not limited to, the factors set forth herein under the heading Plan of
Operations.  MANAGEMENTS DISCUSSION AND ANALYSIS OR
PLAN OF OPERATION  Managements Discussion and Analysis
contains statements that are forward-looking. These statements are based on
current expectations and assumptions that are subject to risks and
uncertainties. Actual results could differ materially because of factors
discussed in Factors That May Affect Future Results and Financial
Condition.  OVERVIEW  We are in a developmental stage.
Implementing our planned business operation is dependant on the effectiveness of
this registration statement and our ability to raise between $600,000 and
$2,000,000 of additional capital after all offering expenses paid to a placement
agent, attorneys, accountants and the like.  13   Our plan is to
utilize such capital we raise as follows:  If a Net of

If a Net of$600,000 is Raised

$2,000,000 is RaisedRenting and Furnishing Offices
$
150,000
$
250,000Patent Application
$
20,000
$
20,000FDA Compliance
$
15,000
$
15,000Equipment
$
80,000
$
280,000Officer Salaries
$
100,000
$
250,000Marketing Expense
$
135,000
$
725,000Working Capital
$
100,000
$
450,000  The foregoing are estimates only and any
funds may be reallocated based upon managements evaluation of then existing
conditions.  INFLATION  Inflation can be expected to have an impact
on our operating costs. A prolonged period of inflation could cause a general
economic downturn and negatively impact our results. However, the effect of
inflation has been minimal over the past three years.  SEASONALITY  We do not believe that our business will be
seasonal to any material degree.  DESCRIPTION OF PROPERTY  We currently operate out of the residence
of our CEO and president Richard Krutosik and will not pay any rent to Mr.
Krutosik until such time as we generate cash flow from our fund raising
activities or operations. When we receive additional funding and need space
beyond our present facility, we believe that we will be able to find ample
suitable space within our projected budget as set forth above.  Item 3. Quantitative and Qualitative
Disclosures About Market Risk  The Company is subject to certain market
risks, including changes in interest rates and currency exchange rates. The
Company does not undertake any specific actions to limit those exposures.  Item 4. Controls and Procedures  An evaluation was carried out under the
supervision and with the participation of our management, including our Chief
Financial Officer and President, of the effectiveness of our disclosure controls
and procedures as of the end of the period covered by this report on Form 10-Q.
Disclosure controls and procedures are procedures that are designed with the
objective of ensuring that information required to be disclosed in our reports
filed under the Securities Exchange Act of 1934, such as this Form 10-Q, is
recorded, processed, summarized and reported, within the time period specified
in the Securities and Exchange Commissions rules and forms, and that such
information is accumulated and is communicated to our management, including our
principal executive and principal financial officers, or persons performing
similar functions, as appropriate, to allow timely decisions regarding required
disclosure. Based on that evaluation, our management concluded that, as of March
31, 2008, our disclosure controls and procedures are effective to satisfy the
objectives for which they are intended.  14   Management's Report on Internal Controls over Financial
Reporting  Internal control over financial reporting
is a process to provide reasonable assurance regarding the reliability of
consolidated financial reporting and the preparation of financial statements for
external purposes in accordance with U.S. generally accepted accounting
principles. There has been no change in the Company's internal control over
financial reporting during the quarter ended March 31, 2008 that has materially
affected, or is reasonably likely to materially affect, the Company's internal
control over financial reporting.  The Company's management, including the
Company's CEO and CAO, does not expect that the Company's disclosure controls
and procedures or the Company's internal controls will prevent all errors and
all fraud. A control system, no matter how well conceived and operated, can
provide only reasonable, not absolute, assurance that the objectives of the
control system are met. Further, the design of a control system must reflect the
fact that there are resource constraints, and the benefits of controls must be
considered relative to their costs. Because of the inherent limitations in all
control systems, no evaluation of the controls can provide absolute assurance
that all control issues and instances of fraud, if any, within the Company have
been detected.  Management conducted an evaluation of the
effectiveness of our internal control over financial reporting based on the
framework in Internal Control - Integrated Framework issued by the Committee of
Sponsoring Organizations of the Treadway Commission. Based on this evaluation,
management concluded that the company's internal control over financial
reporting was effective as of March 31, 2008.  This quarterly report does not include an
attestation report of the Company's registered public accounting firm regarding
internal control over financial reporting. Management's report was not subject
to attestation by the Company's registered public accounting firm pursuant to
temporary rules of the Securities and Exchange Commission that permit the
Company to provide only management's report in this quarterly report.  There were no changes in our internal
control over financial reporting identified in connection with the evaluation
performed that occurred during the fiscal quarter covered by this report that
has materially affected or is reasonably likely to materially affect, our
internal control over financial reporting.  PART II  OTHER INFORMATION  Item 1  Legal Proceedings  The Company is not currently party to any
legal proceedings.  Item 2  Unregistered Sales of Equity
Securities and Use of Proceeds  None.  Item 3  Defaults Upon Senior
Securities  None.  Item 4  Submission of Matters to a Vote
of Security Holders  None.  Item 5  Other Information  None.  15   Item 6 
Exhibits and Reports of Form 8-K  (a)    Exhibits  Exhibit Number
Description31.1
Section 302 Certification Of Chief Executive
Officer and Chief Financial Officer32.1
Certification Pursuant To 18 U.S.C. Section 1350,
As Adopted Pursuant To Section 906 Of The Sarbanes-Oxley Act Of 2002 
Chief Executive Officer and Chief Financial
Officer  (b)    Reports of Form
8-K  None.     SIGNATURE  In accordance with the requirements of the
Securities Exchange Act of 1934, as amended, the registrant caused this Report
on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly
authorized.  NOBLE MEDICAL TECHNOLOGIES

, INC.  Date: May 15, 2008
By:
/s/ Richard KrutosikRichard Krutosik
President, CEO and CFO   16